Andrew Lewis

Originally from Swansea in Wales, Dr Andrew Lewis graduated with his PhD from the University of Cambridge in 2013 under the supervision of Prof Shankar Balasubramanian. During his PhD he worked on the synthesis and biological understanding of quinone containing natural products and their use as anticancer agents. Prior to this, Andrew read Natural Sciences at St Catharine's College, University of Cambridge completing his MSc with Prof Steven Ley working on the synthesis of novel hydrogen bond organocatalysts. From 2013 to 2016 Andrew worked as a postdoctoral fellow at the University of Toronto with Prof Patrick Gunning working on the design and synthesis of protein-protein interaction inhibitors and using chemical biological techniques to understand their mode of action. In 2016 Andrew joined the Huber group at the Target Discovery Institute where his current research involves the use of chemical biology and chemoproteomic techniques to identify novel drug targets for multiple myeloma.